Novartis Q4 Results

Content Click below to navigate through the document Strong FY growth driven by performance from EntrestoⓇ, KesimptaⓇ, KisqaliⓇ and PluvictoⓇ ↓ ↑ Company overview Financial review FY sales Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations References GROWTH Sales Entresto sacubitril/valsartan USD million Growth vs. PY USD million USD growth @ Period Growth vs. PY сс 6,035 1,391 31% Kesimpta (ofatumumab) 2,171 1,079 99% 20 mg injection KISQALI 2,080 849 75% ribociclib "PLUVICTO™ Strong growth (+40% cc); 980 709 261% expected to SCEMBLIX® 413 264 179% (asciminib) 20 mg, 40mg tablets continue LEQVIO® 355 243 217% Cosentyx (secukinumab) ILARIS (canakinumab) 4,980 192 5% 1,355 222 22% istra miezione sottocutanes PROMACTA 2,269 181 10% (eltrombopag) JAKAVI® 1,720 159 12% ruxolitinib Tafinlar. Mekinist. 1,922 152 11% (dabrafenib) (trametinib) Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 49 of Condensed Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. □ NOVARTIS | Reimagining Medicine. Novartis Q4 Results | January 31, 2024 36

View entire presentation